New Study on ADHD Drugs Warns of Cardiovascular Risk

Dec 4, 2023

Key Takeaways

  • A new study confirms a 23% increase in the risk of heart disease among individuals taking ADHD drugs for more than five years compared to those who did not.
  • The study identifies stimulant drugs as being associated with a higher risk of heart-related issues, with each additional year of ADHD drug use linked to an average 4% elevation in the risk of heart disease.
  • CCHR reveals that 3.1 million children aged 0-17 were prescribed ADHD drugs in 2020, and 58,091 children aged 5 and younger were prescribed these drugs.
  • Psychiatric drugs for ADHD have also been linked to psychosis, addiction, and suicide, and non-stimulant drugs have warnings for suicidal ideation and an age limit for usage.
  • The ADHD drug market in the US is estimated to be worth $20 billion annually, and there have been cases of fraudulent marketing and misleading advertising by manufacturers.

CCHR says some of the 9.5 million Americans, including 3.1 million children taking ADHD drugs long-term may be in danger of heart disease, study confirms

Los Angeles, United States - December 4, 2023 /PressCable/ —

With over 9.5 million Americans taking prescription drugs for Attention Deficit Hyperactivity Disorder (ADHD), a new study featured in JAMA Psychiatry serves as a compelling wake-up call regarding the long-term use of these drugs. The Citizens Commission on Human Rights International underscores the significance of these findings. Conducted by Swedish researchers, the study reveals a 23% increase in the risk of heart disease among individuals using ADHD drugs for more than five years compared to those who did not. The researchers tracked individuals diagnosed with ADHD, ranging from ages 6 to 64, for an average period of four years, with some cases spanning up to 14 years between January 2007 and December 2020.[1]

The study identifies stimulant drugs as being associated with a higher risk of heart-related issues. The research shows that each additional year of ADHD drug use was linked to an average 4% elevation in the risk of heart disease, as concluded by the researchers.[2]

CCHR monitors adverse effects of psychiatric drugs and has acquired access to IQVia’s Total Patient Tracker Database for 2020, which reports that 3,155,441 individuals aged 0-17 were prescribed these drugs.[3]

The FDA has approved the use of two categories of psychoactive drugs—stimulants and non-stimulants—in children starting at the age of 6.[4] Below this age, these drugs are not approved. Yet, IQVia statistics reveal that 58,091 children 5 and younger were prescribed ADHD drugs in 2020.

In 2022, Harvard Health Publishing also pointed to research suggesting the drugs may cause a short-term spike in the risk of heart attacks, strokes, and heart rhythm disorders. The findings make sense since stimulants cause the heart to beat faster and with greater force, both of which can raise blood pressure, said Dr. Pieter Cohen, an associate professor of medicine at Harvard Medical School. He referred to a study involving more than 6,400 people ages 66 and older who started stimulant prescriptions between 2017 and 2019. On average, stimulant users were 40% more likely to end up in the emergency room or hospital with a serious heart complication within 30 days of starting the drug.[5] IQVia reported 340,118 Americans aged 65 years and over taking ADHD drugs.

The concern about heart risks has been longstanding. In 2006, an FDA committee voted to recommend a black box warning, the FDA’s most serious warning, for a specific methylphenidate-based stimulant concerning the increased risk of severe cardiovascular events. Several scientific studies have found an increase in the rates of hospitalization for cases of myocardial infarction, stroke, and sudden death in children and adults taking the drug. Between 1999 and 2003, there were 54 reports of non-fatal cardiovascular events and 25 deaths, 19 of which were children, in patients who were taking it.[6]

CCHR says psychiatrists and doctors are taking enormous risks when prescribing these drugs which are also linked to psychosis, addiction, and suicide.[7]

The four FDA-approved non-stimulants include atomoxetine, guanfacine, clonidine and viloxazine.[8] Atomoxetine’s label includes a black box warning for suicidal ideation.[9] Drugs.com specifically indicates “Do not give [clonidine] to a child younger than 6 years old.”[10]

The problem is exacerbated by how subjectively ADHD is diagnosed. There are no brain scans, blood or urine tests, or other medical examinations to determine it. Behaviors on ADHD questionnaires have been criticized because anyone could fall prey to a diagnosis. Symptoms for children and adolescents include:

- “Often fails to give close attention to details or makes careless mistakes in school work….”

- “Often avoids, dislikes, or is reluctant to engage in tasks that require sustained mental effort….”

- “Often fidgets with or taps hands or feet or squirms in seat.”

- “Often unable to play or engage in leisure activities quietly.”

For Adult ADHD, alleged symptoms include impulsiveness, disorganization, problems prioritizing, poor time management skills, problems focusing on a task, trouble multitasking, excessive activity or restlessness, poor planning, low frustration tolerance, hot temper, and trouble coping with stress.

Adult ADHD emerged as a thriving market for drug manufacturers, as highlighted by Fierce Pharma in 2015. Their report indicated that the utilization of ADHD drugs among adults in the U.S. was expanding at a rate almost twice as fast as the overall market growth. The maker of lisdexamfetamine reported that 53% of prescriptions for ADHD drugs in 2014 were for adults, up from 39% in 2007, and amounted to 63 million prescriptions the previous year. This churned out $1.4 billion in sales in 2014.[11]

On August 28, 2023, the FDA approved several generic forms of lisdexamfetamine. Fourteen companies had the go-ahead to manufacture and sell generic versions of the drug. It is estimated that one million Americans regularly take it, generating $2.5 billion in sales annually.[12]

This is a small fraction of the ADHD drug sales that have reached $20 billion a year in the U.S.[13] With it has come fraudulent marketing to increase sales. Between 2000 and 2013, the FDA cited every major ADHD drug manufacturer for false and misleading advertising—some multiple times.[14] In 2013, the manufacturer of lisdexamfetamine agreed to pay $57.5 million in fines to resolve allegations of improper sales and advertising of several ADHD drugs.[15]

CCHR emphasizes the need for a shift in the mental health system’s biomedical model, urging a departure from drugs that carry risks such as psychosis, addiction, cardiac issues, and suicide. As the recent guidelines from the World Health Organization and the United Nations on mental health urges, “there is an overreliance on biomedical approaches and treatment options and inpatient services” and laws should “transition away from a narrow emphasis on biomedical approaches.”[16] CCHR says the warnings associated with these drugs serve as additional evidence supporting the necessity for this paradigm shift.

[1] www.cnn.com/2023/11/22/health/adhd-medication-heart-disease-risk-wellness/index.html; jamanetwork.com/journals/jamapsychiatry/fullarticle/2811812?utm_campaign=articlePDF&utm_medium=articlePDFlink&utm_source=articlePDF&utm_content=jamapsychiatry.2023.4294

[2] www.cnn.com/2023/11/22/health/adhd-medication-heart-disease-risk-wellness/index.html

[3] www.cchrint.org/psychiatric-drugs/children-on-psychiatric-drugs/

[4] www.fda.gov/consumers/consumer-updates/treating-and-dealing-adhd

[5] www.health.harvard.edu/heart-health/how-stimulants-may-affect-your-heart

[6] www.impactlaw.com/dangerous-drugs/concerta

[7] www.cchrint.org/2022/10/07/cchr-warns-children-labeled-adhd/; www.madinamerica.com/2022/05/adhd-money-trail/

[8] www.fda.gov/consumers/consumer-updates/treating-and-dealing-adhd

[9] www.accessdata.fda.gov/drugsatfda_docs/label/2011/021411s035lbl.pdf

[10] www.drugs.com/clonidine.html

[11] www.fiercepharma.com/pharma/adults-are-now-prime-market-for-adhd-drugs-u-s

[12] www.additudemag.com/vyvanse-generics-adhd-medication-fda-approved/

[13] www.cchrint.org/2022/10/07/cchr-warns-children-labeled-adhd/; www.madinamerica.com/2022/05/adhd-money-trail/

[14] www.cchrint.org/2022/10/07/cchr-warns-children-labeled-adhd/; www.nytimes.com/2013/12/15/health/the-selling-of-attention-deficit-disorder.html

[15] www.cchrint.org/2022/10/07/cchr-warns-children-labeled-adhd/

[16] www.cchrint.org/2023/09/18/who-guideline-condemns-coercive-psychiatric-practices/; World Health Organization, OHCHR, “Guidance on Mental Health, Human Rights and Legislation,” 9 Oct. 2023, p. 4

Contact Info:
Name: Amber Rauscher
Email: Send Email
Organization: Citizens Commission on Human Rights International
Address: 6616 Sunset Boulevard, Los Angeles, California 90028, United States
Phone: +1-323-467-4242
Website: https://www.cchrint.org

Source: PressCable

Release ID: 89115136

Should there be any problems, inaccuracies, or doubts arising from the content provided in this press release that require attention or if a press release needs to be taken down, we urge you to notify us immediately by contacting [email protected]. Our efficient team will promptly address your concerns within 8 hours, taking necessary steps to rectify identified issues or assist with the removal process. Providing accurate and dependable information is central to our commitment.

More News

Juliet Daniel changed cancer research. Students of the late Canadian scientist say she also changed lives
Nov 19, 2026
Juliet Daniel changed cancer research. Students of the late Canadian scientist say she also changed lives

Friends, students and colleagues gathered this week at McMaster University in Hamilton to celebrate Juliet Daniel, a Barbadian-Canadian professor and scientist who died April 28 at age 61. They remembered her for her accomplishments in science and for what she brought to the lives of others.

Elevate World collaborates with DCT Abu Dhabi showcasing Luxury Charter Experiences Across Abu Dhabi
Nov 19, 2026
Elevate World collaborates with DCT Abu Dhabi showcasing Luxury Charter Experiences Across Abu Dhabi

Elevate World, a leading travel and tourism group based in the UAE, has collaborated with the Department of Culture and Tourism – Abu Dhabi (DCT Abu Dhabi) on an initiative to support the growth of luxury yacht and maritime tourism in the emirate, and strengthen Abu Dhabi’s position as a global destination for high-end travel experiences tailored to visitors’ preferences. The initiative aims to empower tour operators, yacht charter brokers and luxury travel advisors worldwide to create integrated itineraries that go beyond traditional cruises. By bringing together private yacht journeys, luxury accommodation, fine dining, cultural landmarks and exceptional experiences, travel partners can develop itineraries shaped around each guest’s interests and length of stay.

Ausprobiert: Four Seasons Casablanca – eine moderne und zugleich typisch marokkanische Adresse
Nov 19, 2026
Ausprobiert: Four Seasons Casablanca – eine moderne und zugleich typisch marokkanische Adresse

Es gibt Hotels, in denen man ankommt, eincheckt und dann einfach weiterreist. Und dann gibt es Hotels, die das Tempo und den Sinn des eigenen Aufenthalts sofort verändern. Das Four Seasons Casablanca gehört definitiv zur zweiten Kategorie. The post Ausprobiert: Four Seasons Casablanca – eine moderne und zugleich typisch marokkanische Adresse appeared first on Business Traveller.

FITUR 2027 to Expand with Two New Halls
Nov 19, 2026
FITUR 2027 to Expand with Two New Halls

FITUR 2027, the International Tourism Trade Fair organized by IFEMA MADRID, will take place from 20 to 24 January 2027, with Puerto Rico as Partner Country, in an edition defined by growth, specialization and innovation across the tourism sector. With the addition of two new exhibition halls, the event will further expand its scale and capacity, responding to growing demand from destinations, tourism businesses and industry professionals worldwide.

Ras Al Khaimah Sets the Stage for an Unforgettable New Year’s Eve With a Spectacular Sky Show
Nov 19, 2026
Ras Al Khaimah Sets the Stage for an Unforgettable New Year’s Eve With a Spectacular Sky Show

Ras Al Khaimah will welcome 2027 with an 11-hour festival that ends in a midnight sky show over the waterfront stretching five kilometres between Al Marjan Island and Al Hamra. Combining fireworks, synchronised drones and music, the show will bring to life this year’s theme, “New Horizons”, which captures the spirit of looking forward, dreaming bigger and embracing the promise of a new year.  The Ras Al Khaimah New Year’s Eve Festival running from 4 PM on 31 December until 3 AM on 1 January, will take the festivities to another level. Festivalgoers can look forward to an evening of world-class entertainment with five international DJs sets, three spectacular roaming parade shows and an MC building the anticipation to the midnight sky show and keeping the celebrations going well into 2027 at the after-party.

Anguilla showcases diving experiences and Caribbean flavor at DEMA Show in New Orleans
Nov 19, 2026
Anguilla showcases diving experiences and Caribbean flavor at DEMA Show in New Orleans

Seeking to capture a greater share of the Caribbean’s valuable dive tourism market, the Anguilla Tourist Board showcased the destination’s underwater treasures, local flavors and welcoming hospitality at the 2026 DEMA Show, held Nov. 3-6 at the Ernest N. Morial Convention Center. Dive tourism is an important segment of the Caribbean’s visitor economy, generating revenue for dive operators, accommodation providers, restaurants and other tourism-related businesses while reinforcing the importance of protecting the region’s marine ecosystems.

ATTA® ANNOUNCES HospitableMe AS EXPERT PARTNER
Nov 19, 2026
ATTA® ANNOUNCES HospitableMe AS EXPERT PARTNER

The African Travel and Tourism Association (ATTA®) has announced a new partnership with HospitableMe, a global leader in inclusive hospitality, naming the organisation its Expert Partner for Inclusive Welcome. The partnership will provide ATTA® members with access to practical training, dedicated webinars, educational resources and specialist expertise as well as preferential rates for HospitableMe’s specialist training and services, which will all help tourism businesses better understand and respond to the needs of an increasingly diverse international travel market.

Yas Marina Unveils Race Week Dining and Entertainment Line-Up
Nov 19, 2026
Yas Marina Unveils Race Week Dining and Entertainment Line-Up

The excitement doesn’t stop at the racetrack! This Race Weekend, Yas Marina invites visitors to soak up the celebratory atmosphere with an exciting line-up of waterfront dining experiences, exclusive pop-ups, themed activations and late-night entertainment. This December, Yas Marina promises plenty of reasons to visit, celebrate and make the most of the festivities, both on and off track.

Sir Stephen Hough dazzles Hong Kong with Schubert, Beethoven and Mary Poppins magic
Nov 19, 2026
Sir Stephen Hough dazzles Hong Kong with Schubert, Beethoven and Mary Poppins magic

A palpable buzz of anticipation filled a packed Hong Kong City Hall as Sir Stephen Hough, the British-Australian virtuoso, composer, writer and poet, walked on to the stage on November 17. Hough, who turns 65 on November 22, reminded the audience that he made his Hong Kong debut on that stage in 1984 – and he still exudes the same zesty energy and cheeky-chappy smile, quite untouched by the almost 40 years since I first heard him at the BBC Proms in 1988. So what has changed? I have heard him...

Sun, Surf and Style: Hyatt’s Andaz Makes Australian Debut on the Gold Coast
Nov 19, 2026
Sun, Surf and Style: Hyatt’s Andaz Makes Australian Debut on the Gold Coast

Hyatt’s lifestyle brand debuts in Australia with 202 rooms, a fire-led Mediterranean restaurant and a pool deck that welcomes locals as well as guests The post Sun, Surf and Style: Hyatt’s Andaz Makes Australian Debut on the Gold Coast appeared first on Business Traveller.

Eri Maldives Unveils Boduai Thila: A New Unexplored Dive Site in North Malé Atoll
Nov 19, 2026
Eri Maldives Unveils Boduai Thila: A New Unexplored Dive Site in North Malé Atoll

When did a Maldivian dive site last feel genuinely new? Eri Maldives, the vibrant island resort in North Malé Atoll, has added Boduai Thila to its dive catalogue: a sprawling network of underwater pinnacles that, for now, remains largely uncharted. Opening to divers of every level, from freshly certified beginners to seasoned underwater photographers, the site arrives alongside a new fluorescent night dive and snorkel on the resort’s own house reef.

Discover Elevated Island Living with Luxury Group by Marriott International in the Maldives
Nov 19, 2026
Discover Elevated Island Living with Luxury Group by Marriott International in the Maldives

A private villa becomes a gathering place for three generations; a yacht journey unfolds into an intimate anniversary celebration; an encounter with Maldivian traditions reveals the stories, craftsmanship, and cultural heritage. In the Maldives, luxury takes shape around the people, occasions, and discoveries that make each journey personal. Through its Endless Summer 2027 offer, the Luxury Group by Marriott International invites couples, families, friends, and solo travelers to discover elevated island living beyond the ordinary at five luxury resorts in the Maldives.

YOUR NEWS, OUR NETWORK.

Do you have Great News you want to tell the world?

Be it updates about your business or your community, you can make sure that it’s heard by submitting your story to our network reaching hundreds of news sites across 6 verticals.

Life Ponds

Life Ponds publishes travel and lifestyle on a daily basis. We believe that Life Ponds will help to solve your problems every time you face a challenge.

Newsletter